[article]
| Titre : |
Targeted treatments in autism and fragile X syndrome |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Kağan GURKAN C., Auteur ; Randi J. HAGERMAN, Auteur |
| Année de publication : |
2012 |
| Article en page(s) : |
p.1311-1320 |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Fragile X syndrome Autism mGluR GABA Treatment |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABAB agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X-associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism. |
| En ligne : |
http://dx.doi.org/10.1016/j.rasd.2012.05.007 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=165 |
in Research in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1311-1320
[article] Targeted treatments in autism and fragile X syndrome [Texte imprimé et/ou numérique] / Kağan GURKAN C., Auteur ; Randi J. HAGERMAN, Auteur . - 2012 . - p.1311-1320. Langues : Anglais ( eng) in Research in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1311-1320
| Mots-clés : |
Fragile X syndrome Autism mGluR GABA Treatment |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABAB agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X-associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism. |
| En ligne : |
http://dx.doi.org/10.1016/j.rasd.2012.05.007 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=165 |
|  |
Targeted treatments in autism and fragile X syndrome in Research in Autism Spectrum Disorders, 6-4 (October-December 2012)
